It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Antiretroviral therapy (ART) has extended the lifespan of people living with HIV/AIDS (PLHIV), exposing them to a higher risk of cardiovascular diseases (CVD). Hypertension (HTN), the primary contributor to CVD burden, is increasingly concerning for PLHIV. This study aimed to assess the prevalence and associated factors of hypertension in PLHIV on ART at the National Teaching Hospital Hubert Koutoukou Maga (HKM) of Benin using a prospective cross-sectional study conducted between October and December 2021. Patients who had a systolic blood pressure ≥ 140 mmHg or/and diastolic blood pressure ≥ 90 mmHg or/and current use of antihypertensive medication from medical records were considered to have HTN. A total of 352 patients, including 260 women with a sex ratio of 0.3 were included. The mean age was 42.9 ± 11.9 years. Most patients were educated and did not use tobacco. 42.0% were current alcohol drinkers. The duration of ART treatment ranged from 0 to 22 years, with a median duration of 5.0 years. 14.2% were hypertensives with 3.1% newly diagnosed and 11.1% known with hypertension. Age above 40 years, living with a partner, alcohol consumption and body mass index greater than 25 were significantly associated with HTN. HTN in PLHIV is associated with numerous factors. Reducing the burden of the disease in target people in Benin requires a wide range of actions that need to be implemented.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Abomey Calavi, Ecole Doctorale des Sciences de la Santé (EDSS), Abomey Calavi, Benin (GRID:grid.412037.3) (ISNI:0000 0001 0382 0205); Laboratoire ses Maladies Chroniques et Neurologiques (LEMACEN), Abomey Calavi, Benin (GRID:grid.412037.3)
2 Holo Global Health Research Institute, Cotonou, Benin (GRID:grid.412037.3); Health Data Acumen, Cotonou, Benin (GRID:grid.412037.3); University of Nairobi, Institute of Tropical and Infectious Diseases, Nairobi, Kenya (GRID:grid.10604.33) (ISNI:0000 0001 2019 0495)
3 Holo Global Health Research Institute, Cotonou, Benin (GRID:grid.10604.33)
4 University of Parakou, Ecole Nationale de Formation des Techniciens Supérieurs en Santé Publique et Surveillance Epidémiologique (ENATSE), Parakou, Benin (GRID:grid.440525.2) (ISNI:0000 0004 0457 5047)
5 University of Abomey Calavi, Faculty of Health Sciences, Abomey Calavi, Benin (GRID:grid.412037.3) (ISNI:0000 0001 0382 0205)
6 Holo Global Health Research Institute, Cotonou, Benin (GRID:grid.412037.3); Health Data Acumen, Cotonou, Benin (GRID:grid.412037.3)
7 Holo Global Health Research Institute, Cotonou, Benin (GRID:grid.412037.3); University of San Francisco, Division of Cardiology, Department of Medicine, San Francisco, USA (GRID:grid.267103.1) (ISNI:0000 0004 0461 8879)